US2010087621A1PendingUtilityA1
Immune reactivity to her-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
Est. expiryMar 17, 2013(expired)· nominal 20-yr term from priority
C07K 14/4705A61K 38/00G01N 2333/82G01N 2333/71Y10S530/828Y10S530/806C07K 14/71A61P 35/00A61P 43/00A61P 37/00G01N 33/57585G01N 33/57557A61K 40/4205A61K 40/11C07K 7/06A61K 39/001106A61K 39/00C12N 15/11C12N 15/86
74
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.
Claims
exact text as granted — not AI-modified1 . An isolated peptide consisting of one of the amino acid sequences:
(Seq. ID No. 26)
Gln-Leu-Phe-Glu-Asp-Asn-Tyr-Ala-Leu;
(Seq. ID No. 27)
Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Leu;
(Seq. ID No. 29)
Val-Met-Ala-Gly-Val-Gly-Ser-Pro-Tyr-Val;
2 . An isolated peptide according to claim 1 consisting of the amino acid sequence of Gln-Leu-Phe-Glu-Asp-Asn-Tyr-Ala-Leu (Seq. ID No. 26).
3 . An isolated peptide according to claim 1 consisting of the amino acid sequence of Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Leu (Seq. ID No. 27).
4 . An isolated peptide according to claim 1 consisting of the amino acid sequence of Val-Met-Ala-Gly-Val-Gly-Ser-Pro-Tyr-Val (Seq. ID No. 29).Join the waitlist — get patent alerts
Track US2010087621A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.